211 related articles for article (PubMed ID: 36016940)
1. Inactivated vaccine Covaxin/BBV152: A systematic review.
Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
Front Immunol; 2022; 13():863162. PubMed ID: 36016940
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Ella R; Vadrevu KM; Jogdand H; Prasad S; Reddy S; Sarangi V; Ganneru B; Sapkal G; Yadav P; Abraham P; Panda S; Gupta N; Reddy P; Verma S; Kumar Rai S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Rao V; Guleria R; Ella K; Bhargava B
Lancet Infect Dis; 2021 May; 21(5):637-646. PubMed ID: 33485468
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
Sunagar R; Prasad SD; Ella R; Vadrevu KM
Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
[TBL] [Abstract][Full Text] [Related]
8. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
[TBL] [Abstract][Full Text] [Related]
9. Covid-19 Vaccines Available in India.
Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
Vadrevu KM; Reddy S; Jogdand H; Ganneru B; Mirza N; Tripathy VN; Singh C; Khalatkar V; Prasanth S; Rai S; Ella R; Blackwelder W; Prasad S; Ella K
Lancet Infect Dis; 2022 Sep; 22(9):1303-1312. PubMed ID: 35717995
[TBL] [Abstract][Full Text] [Related]
11. Covaxin: An overview of its immunogenicity and safety trials in India.
Sharma R; Tiwari S; Dixit A
Bioinformation; 2021; 17(10):840-845. PubMed ID: 35574502
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior vaccination with Covishield
Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
Yadav PD; Sardana V; Deshpande GR; Shinde PV; Thangaraj JWV; George LS; Sapkal GN; Patil DY; Sahay RR; Shete AM; Joshi M; Murhekar M; Godbole S; Gupta N; Prakash S; Rathore M; Ujjainiya R; Singh AP; Mishra A; Dash D; Chaudhary K; Sengupta S;
Indian J Med Res; 2024 Feb; 159(2):223-231. PubMed ID: 38517215
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.
Das S; Kar SS; Samanta S; Banerjee J; Giri B; Dash SK
Immunol Res; 2022 Jun; 70(3):289-315. PubMed ID: 35192185
[TBL] [Abstract][Full Text] [Related]
15. Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
Chaudhary A; Madhavan R; Babji S; Raju R; Syed C; Kumar A; Saravanan P; Sharon Nikitha O; Leander Xavier JV; David Chelladurai JS; Deborah AA; George A; Kang G; Rose W
Vaccine; 2023 Jul; 41(33):4808-4822. PubMed ID: 37357073
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
[TBL] [Abstract][Full Text] [Related]
18. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects.
Dotiwala F; Upadhyay AK
Front Immunol; 2022; 13():940715. PubMed ID: 36177016
[TBL] [Abstract][Full Text] [Related]
20. A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys.
Singh P; Ujjainiya R; Prakash S; Naushin S; Sardana V; Bhatheja N; Singh AP; Barman J; Kumar K; Gayali S; Khan R; Rawat BS; Tallapaka KB; Anumalla M; Lahiri A; Kar S; Bhosale V; Srivastava M; Mugale MN; Pandey CP; Khan S; Katiyar S; Raj D; Ishteyaque S; Khanka S; Rani A; Promila ; Sharma J; Seth A; Dutta M; Saurabh N; Veerapandian M; Venkatachalam G; Bansal D; Gupta D; Halami PM; Peddha MS; Veeranna RP; Pal A; Singh RK; Anandasadagopan SK; Karuppanan P; Rahman SN; Selvakumar G; Venkatesan S; Karmakar MK; Sardana HK; Kothari A; Parihar DS; Thakur A; Saifi A; Gupta N; Singh Y; Reddu R; Gautam R; Mishra A; Mishra A; Gogeri I; Rayasam G; Padwad Y; Patial V; Hallan V; Singh D; Tirpude N; Chakrabarti P; Maity SK; Ganguly D; Sistla R; Balthu NK; A KK; Ranjith S; Kumar BV; Jamwal PS; Wali A; Ahmed S; Chouhan R; Gandhi SG; Sharma N; Rai G; Irshad F; Jamwal VL; Paddar MA; Khan SU; Malik F; Ghosh D; Thakkar G; Barik SK; Tripathi P; Satija YK; Mohanty S; Khan MT; Subudhi U; Sen P; Kumar R; Bhardwaj A; Gupta P; Sharma D; Tuli A; Ray Chaudhuri S; Krishnamurthi S; Prakash L; Rao CV; Singh BN; Chaurasiya A; Chaurasiyar M; Bhadange M; Likhitkar B; Mohite S; Patil Y; Kulkarni M; Joshi R; Pandya V; Mahajan S; Patil A; Samson R; Vare T; Dharne M; Giri A; Mahajan S; Paranjape S; Sastry GN; Kalita J; Phukan T; Manna P; Romi W; Bharali P; Ozah D; Sahu RK; Dutta P; Singh MG; Gogoi G; Tapadar YB; Babu EV; Sukumaran RK; Nair AR; Puthiyamadam A; Valappil PK; Pillai Prasannakumari AV; Chodankar K; Damare S; Agrawal VV; Chaudhary K; Agrawal A; Sengupta S; Dash D
Comput Biol Med; 2022 Jul; 146():105419. PubMed ID: 35483225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
